marked.bio

anti-CD20 antibody · antibody

rituximab

6 active trials across 4 of our biomarkers, targeting CD20. Not approved for any biomarker on marked.bio yet.

Also known as MabThera, Rituxan.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 3 Phase 2
FLT3 mutation (ITD/TKD) 2 6 Phase 3
ALK fusion 1 2 Phase 3
IDH1/2 mutation 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of rituximab.

  1. Incyte 1

Trials

6 of 12 trials shown

  1. Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

    Active, not recruiting Phase 3 Children's Oncology Group Started 2023Primary completion 2026-06 NCT05457556

    BusulfancyclophosphamidefludarabineLapine T-Lymphocyte Immune GlobulinmelphalanmethotrexateMycophenolate MofetilrituximabtacrolimusThiotepa

    FLT3/ITD+ with allelic ratio \> 0.1 without bZIP CEBPA, NPM1

    FLT3 mutation (ITD/TKD)Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome

  2. Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

    Active, not recruiting Phase 3 Incyte Started 2021Primary completion 2026-09 NCT04824092

    TafasitamabLenalidomiderituximabcyclophosphamidedoxorubicinvincristineprednisoneTafasitamab placeboLenalidomide placebo

    Anaplastic lymphoma kinase (ALK)-positive large BCL

    ALK fusionDiffuse Large B-cell Lymphoma

  3. Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

    Recruiting Phase 1/2 National Cancer Institute (NCI) Started 2026Primary completion 2030-03 NCT06965114

    cladribinerituximabtovorafenib FDA EU

    …ly confirmed diagnosis of classical hairy cell leukemia (HCL), including demonstration of BRAF V600E mutation by immunohistochemistry, molecular diagnostic testing, or polymerase chain react…

    BRAF V600EHairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia

  4. A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024Primary completion 2027-09 NCT06561360

    vemurafenib FDA EUObinutuzumabcladribinerituximab

    Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry.

    BRAF V600EHairy Cell Leukemia

  5. A Study of Enasidenib in People With T-Cell Lymphoma

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024Primary completion 2027-12 NCT06756308

    enasidenib FDArituximab

    Pathologically-confirmed AITL at the enrolling institution, with confirmed IDH2 mutation (by MSK ddPCR).

    IDH1/2 mutationT-cell Lymphoma

  6. T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

    Active, not recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2018Primary completion 2027-05 NCT03531736

    Antithymocyte globulin (Rabbit)fludarabinecyclophosphamiderituximab

    Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any others that are considered to be high risk

    FLT3 mutation (ITD/TKD)Myeloid Diseases